Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Gynecol Endocrinol. 2023 Dec;39(1):2242951. doi: 10.1080/09513590.2023.2242951.
To analyze pregnancy outcomes of women with one abnormal value (OAV) during oral glucose tolerance test (OGTT) or OGTT-intolerance, compared with gestational diabetes mellitus (GDM) and normal glucose tolerance (NGT) pregnant women, according to whether they received any health intervention or not.
An observational retrospective study was designed including pregnant women who gave birth at Hospital del Mar, Barcelona (Spain) during December/2014-July/2018. Baseline characteristics, pregnancy outcomes and health interventions were obtained from a database collected previously for other study. Inclusion criteria were singleton pregnancies with OAV or OGTT-intolerants who gave birth at the Hospital. GDM screening followed a two-step approach: 50 g O'Sullivan test and 100 g 3-hour OGTT if the former was abnormal.
From a total of 2,662 pregnancies, 326 (12.2%) had GDM, 87 OAV (3.3%), 65 OGTT intolerance (2.4%) and 2,184 were NGT women. First trimester HbA1c in both OAV and OGTT-intolerant women was significantly higher than in NGT group, and significantly lower than in GDM pregnants. No differences in obstetric outcomes were found between OGTT-intolerants and NGT/GDM groups. Treated OGTT-intolerants had greater gestational age at delivery than non-treated ones (weeks, 39.6 ± 1.2 vs 38.0 ± 4.0, respectively). In OAV women, significant differences were observed in newborns' birthweight (g, 3227.3 ± 500.8 vs 3351.1 ± 436.7, vs GDM) and gestational age at birth (weeks, 38.7 ± 1.8 vs 39.3 ± 1.9, vs NGT), but not in macrosomia/pre-eclampsia. No differences were found according to treatment in OAV.
OAV and OGTT-intolerants account for a third of pregnant women referred to Diabetes Unit. Their rates of preterm birth, pre-eclampsia and macrosomia were not different from NGT or GDM women.
分析口服葡萄糖耐量试验(OGTT)或 OGTT 不耐受时仅一项异常值(OAV)的孕妇与妊娠期糖尿病(GDM)和正常糖耐量(NGT)孕妇的妊娠结局,根据是否接受任何健康干预措施进行分组。
本研究为观察性回顾性研究,纳入 2014 年 12 月至 2018 年 7 月在巴塞罗那德玛尔医院分娩的孕妇。从之前为其他研究收集的数据库中获取基线特征、妊娠结局和健康干预措施。纳入标准为在该医院分娩的单胎妊娠伴 OAV 或 OGTT 不耐受的孕妇。GDM 筛查采用两步法:50g O'Sullivan 试验,若结果异常则行 100g 3 小时 OGTT。
在总共 2662 例妊娠中,326 例(12.2%)患有 GDM,87 例(3.3%)为 OAV,65 例(2.4%)为 OGTT 不耐受,2184 例为 NGT 孕妇。OAV 和 OGTT 不耐受孕妇的初诊 HbA1c 均显著高于 NGT 组,显著低于 GDM 孕妇。OGTT 不耐受与 NGT/GDM 组的产科结局无差异。经治疗的 OGTT 不耐受孕妇的分娩孕周大于未经治疗的孕妇(周,39.6±1.2 与 38.0±4.0,分别)。OAV 孕妇的新生儿出生体重(g,3227.3±500.8 与 3351.1±436.7,与 GDM 比较)和分娩孕周(周,38.7±1.8 与 39.3±1.9,与 NGT 比较)存在显著差异,但巨大儿/子痫前期发生率无差异。OAV 孕妇根据治疗措施的不同无差异。
OGTT 不耐受和 OAV 占转诊至糖尿病科孕妇的三分之一。其早产、子痫前期和巨大儿的发生率与 NGT 或 GDM 孕妇无差异。